ProMIS Neurosciences Highlights New Peer-Reviewed Publication Showing Plasma pTau as Predictive Early Endpoint in Alzheimer's Trials Supporting PRECISE-AD
Benzinga Newsdesk 11 months ago
News
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trialProMIS on track to leverage new plasma pTau insights with
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial
ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout